Appl. No. 10/667,290 Amdt. dated June 8, 2007 Reply to Office Action of March 23, 2007

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

## Listing of Claims:

Claims 1-23. (Canceled).

Claim 24. (Currently amended) A substantially pure or recombinant antigenic polypeptide comprising a sequence having at least 70% sequence identity with of SEQ ID NO:2

Claim 25. (Currently amended) The polypeptide of Claim 24 comprising a sequence having at least 90% sequence identity with SEQ ID NO:2, wherein the polypeptide comprises:

- a) residues 1-101 of SEQ ID NO:2;
- b) residues 102-195 of SEQ ID NO:2;
- c) residues 196-297 of SEQ ID NO:2;
- d) residues 1-328 of SEQ ID NO:2; or
  - e) residues 1-606 of SEQ ID NO:2.

Claim 26. (Currently amended) A heterodimeric composition comprising the polypeptide of Claim 24 and  $\underline{human}$  IL-12R $\beta$ 1.

Claim 27. (Currently amended) The composition of Claim 26 capable of binding <u>human</u> IL-B30/p40.

Claim 28. (Previously presented) A kit comprising the polypeptide of Claim 24 and instructions for use.

Claim 29. (Currently amended) The kit of Claim 28, wherein the kit also contains:

a) human IL-12Rβ1 polypeptide;

Atty.Dkt. DX01074B1 Page 3 of 8

Appl. No. 10/667,290 Amdt. dated June 8, 2007 Reply to Office Action of March 23, 2007

- b) human p40[[,]];
- c) human IL-B30[[,]]; or
- d) human IL-B30/p40 polypeptides: or
- c) an antibody having binding affinity for SEQ ID NO:2.

Claims 30-38. (Canceled).

Claim 39. (New) The polypeptide of Claim 24 comprising a sequence having fewer than 5 substitutions relative to the sequence of SEQ ID NO:2.

Claim 40. (New) The polypeptide of Claim 24 comprising a sequence having at least 95% sequence identity with SEQ ID NO:2.

Claim 41. (New) The polypeptide of Claim 24 comprising a sequence having at least 98% sequence identity with SEQ ID NO:2.

Claim 42. (New) The polypeptide of Claim 24, wherein the polypeptide, when combined with IL-12R\(\beta\), is able to form a functional receptor complex for p40/IL-B30.

Claim 43. (New) The polypeptide of Claim 25, wherein the polypeptide, when combined with IL-12Rβ1, is able to form a functional receptor complex for p40/IL-B30.

Claim 44. (New) The polypeptide of Claim 39, wherein the polypeptide, when combined with IL-12RB1, is able to form a functional receptor complex for p40/IL-B30.

Claim 45. (New) The polypeptide of Claim 40, wherein the polypeptide, when combined with IL-12Rβ1, is able to form a functional receptor complex for p40/IL-B30.

Claim 46. (New) The polypeptide of Claim 41, wherein the polypeptide, when combined with IL-12R\(\text{B1}\), is able to form a functional receptor complex for p40/IL-B30.

Atty.Dkt. DX01074B1 Page 4 of 8